Literature DB >> 21594892

JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis.

Valerio De Stefano1, Elena Rossi, Tommaso Za, Angela Ciminello, Silvia Betti, Claudia Luzzi, Giuseppe Leone, Patrizia Chiusolo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21594892     DOI： 10.1002/ajh.22024

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  11 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

Review 2.  Cerebral sinus-venous thrombosis.

Authors:  Ida Martinelli; Serena Maria Passamonti; Elena Rossi; Valerio De Stefano
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

3.  The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.

Authors:  Youwen Qin; Xiaorui Wang; Chuxian Zhao; Chun Wang; Yining Yang
Journal:  Int J Hematol       Date:  2015-05-22       Impact factor: 2.490

4.  Budd-Chiari Syndrome in a Patient with JAK-2 V617F and Factor V G1691A Mutations.

Authors:  J S Velarde-Félix; J Sanchez-Zazueta; F P Gonzalez-Ibarra; J A González-Valdez; B Salcido-Gómez; E Gallardo-Angulo; J Murillo-Llanes
Journal:  West Indian Med J       Date:  2014-06-10       Impact factor: 0.171

5.  Initial management of noncirrhotic splanchnic vein thrombosis: when is anticoagulation enough?

Authors:  Pranavi Ravichandran; Kris P Croome; Michael J Kovacs; Alejandro Lazo-Langner; Roberto Hernandez-Alejandro
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04

6.  Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis.

Authors:  Antonella Tufano; Anna Guida; Antonio Coppola; Assunta Nardo; Mirko Di Capua; Gabriele Quintavalle; Matteo Nicola Dario Di Minno; Anna Maria Cerbone; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-02-06       Impact factor: 3.443

Review 7.  Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis.

Authors:  Mohsen Maleknia; Saeid Shahrabi; Majid Ghanavat; Tina Vosoughi; Najmaldin Saki
Journal:  Mol Biol Rep       Date:  2020-05-30       Impact factor: 2.316

8.  Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.

Authors:  Valerio De Stefano; Guido Finazzi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-06-26       Impact factor: 11.037

9.  Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.

Authors:  Jung-Sook Ha; Yu-Kyung Kim; Soon-Il Jung; He-Ra Jung; In-Sung Chung
Journal:  Ann Lab Med       Date:  2012-10-17       Impact factor: 3.464

10.  Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report.

Authors:  Jian Xie; Leiyu Geng; Baoyu Yuan; Yijing Guo; Zhijun Zhang
Journal:  BMC Neurol       Date:  2020-11-07       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.